A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01767311

Recruitment Status : Active, not recruiting

First Posted : January 14, 2013

Last Update Posted : May 3, 2023

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborator:

Biogen

Information provided by (Responsible Party):

Eisai Inc.

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	February 20, 2025
Estimated Study Completion Date :	February 20, 2025

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H, Rabe M, Koyama A, Reyderman L, Berry DA, Berry S, Gordon R, Kramer LD, Cummings JL. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Abeta protofibril antibody. Alzheimers Res Ther. 2021 Apr 17;13(1):80. doi: 10.1186/s13195-021-00813-8. Erratum In: Alzheimers Res Ther. 2022 May 21;14(1):70.

To Top